0A2V Stock Overview
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Sanofi Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €47.99 |
| 52 Week High | €58.92 |
| 52 Week Low | €45.00 |
| Beta | 0.45 |
| 11 Month Change | -9.38% |
| 3 Month Change | -14.41% |
| 1 Year Change | 1.82% |
| 33 Year Change | -0.66% |
| 5 Year Change | 2.85% |
| Change since IPO | 4.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0A2V | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -0.4% | -2.3% | 0.8% |
| 1Y | 1.8% | -2.7% | 6.6% |
Return vs Industry: 0A2V exceeded the UK Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: 0A2V underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| 0A2V volatility | |
|---|---|
| 0A2V Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0A2V has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0A2V's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 86,088 | Paul Hudson | www.sanofi.com |
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Sanofi Fundamentals Summary
| 0A2V fundamental statistics | |
|---|---|
| Market cap | US$119.21b |
| Earnings (TTM) | US$4.72b |
| Revenue (TTM) | US$50.70b |
25.3x
P/E Ratio2.4x
P/S RatioIs 0A2V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0A2V income statement (TTM) | |
|---|---|
| Revenue | €48.45b |
| Cost of Revenue | €14.96b |
| Gross Profit | €33.48b |
| Other Expenses | €28.98b |
| Earnings | €4.51b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 30, 2025
| Earnings per share (EPS) | 3.59 |
| Gross Margin | 69.12% |
| Net Profit Margin | 9.30% |
| Debt/Equity Ratio | 32.5% |
How did 0A2V perform over the long term?
See historical performance and comparison